Skip to main content
Top
Published in: Pathology & Oncology Research 2/2020

Open Access 01-04-2020 | Salivary Gland Cancer | Original Article

AF1q Expression Associates with CD44 and STAT3 and Impairs Overall Survival in Adenoid Cystic Carcinoma of the Head and Neck

Authors: Lorenz C. Kadletz, Faris F. Brkic, Bernhard J. Jank, Sven Schneider, Julia Cede, Rudolf Seemann, Elisabeth S. Gruber, Elisabeth Gurnhofer, Gregor Heiduschka, Lukas Kenner

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Salivary gland malignancies of the head and neck form a heterogeneous group. Adenoid cystic carcinomas are an aggressive entity of salivary gland malignancies characterized by frequent distant metastases and poor response to radio- and chemotherapy. AF1Q is a MLL fusion partner, which can activate Wnt and STAT3 signaling. Recently, overexpression of AF1q has been identified as a poor prognosticator in patients of different malignancies. A total of 46 patients with adenoid cystic carcinoma were immunohistochemically evaluated for expression of AF1q and clinical outcome was analyzed in this context. Additionally, STAT3 and the Wnt downstream target CD44 were investigated and correlated with AF1q. AF1q was overexpressed in 52.2%. Overexpression of AF1q was associated with poorer overall survival (p = 0.03). Additionally, lymph node metastases and solid tumor parts were more frequently observed in AF1qhigh patients (p = 0.07 and 0.05, respectively). AF1q did not influence the occurrence of distant metastases. Expression of AF1q was associated with higher levels of STAT3 and CD44 (p = 0.003 and 0.006, respectively). AF1q is a novel prognostic marker for poor overall survival in adenoid cystic carcinoma patients. The deleterious effects on survival may be a result of promotion of the STAT3 and Wnt pathway.
Literature
2.
go back to reference Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck Tumours. IARC Press Barnes L, Eveson JW, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck Tumours. IARC Press
3.
go back to reference Dockerty MB, Mayo CW (1942) Surg Gynecol Obstet 1033 Dockerty MB, Mayo CW (1942) Surg Gynecol Obstet 1033
5.
go back to reference van Weert S, Reinhard R, Bloemena E, Buter J, Witte BI, Vergeer MR, Leemans CR (2016) Head Neck 39:456CrossRef van Weert S, Reinhard R, Bloemena E, Buter J, Witte BI, Vergeer MR, Leemans CR (2016) Head Neck 39:456CrossRef
6.
go back to reference Fordice J, Kershaw C, El-Naggar A, Goepfert H (1999) Arch Otolaryngol Head Neck Surg 125:149CrossRef Fordice J, Kershaw C, El-Naggar A, Goepfert H (1999) Arch Otolaryngol Head Neck Surg 125:149CrossRef
7.
go back to reference Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, Ji C, Bunting ST, Wang Z, Shoham M, Huang G, Bago-Horvath Z, Gibson LF, Rojanasakul Y, Remick S, Ivanov A, Pugacheva E, Bunting KD, Moriggl R, Kenner L, Tse W (2015) Oncotarget 6(20697) Park J, Schlederer M, Schreiber M, Ice R, Merkel O, Bilban M, Hofbauer S, Kim S, Addison J, Zou J, Ji C, Bunting ST, Wang Z, Shoham M, Huang G, Bago-Horvath Z, Gibson LF, Rojanasakul Y, Remick S, Ivanov A, Pugacheva E, Bunting KD, Moriggl R, Kenner L, Tse W (2015) Oncotarget 6(20697)
9.
go back to reference Co NN, Tsang WP, Tsang TY, Yeung CLA, Yau PL, Kong SK, Kwok TT (2010) Oncol Rep 24:547PubMed Co NN, Tsang WP, Tsang TY, Yeung CLA, Yau PL, Kong SK, Kwok TT (2010) Oncol Rep 24:547PubMed
10.
go back to reference Tiberio P, Cavadini E, Callari M, Daidone MG, Appierto V (2012) PLoS One 7:e39968CrossRef Tiberio P, Cavadini E, Callari M, Daidone MG, Appierto V (2012) PLoS One 7:e39968CrossRef
11.
go back to reference Wang R, Geng N, Zhou Y, Zhang D, Li L, Li J, Ji N, Zhou M, Chen Y, Chen Q (2015) Biomed Mater Eng 26:S2145PubMed Wang R, Geng N, Zhou Y, Zhang D, Li L, Li J, Ji N, Zhou M, Chen Y, Chen Q (2015) Biomed Mater Eng 26:S2145PubMed
12.
go back to reference Schneider S, Thurnher D, Seemann R, Brunner M, Kadletz L, Ghanim B, Aumayr K, Heiduschka G, Lill C (2015) Eur Arch Otorhinolaryngol 273:1283CrossRef Schneider S, Thurnher D, Seemann R, Brunner M, Kadletz L, Ghanim B, Aumayr K, Heiduschka G, Lill C (2015) Eur Arch Otorhinolaryngol 273:1283CrossRef
13.
go back to reference Lill C, Schneider S, Seemann R, Kadletz L, Aumayr K, Ghanim B, Thurnher D (2014) Head Neck 37:30CrossRef Lill C, Schneider S, Seemann R, Kadletz L, Aumayr K, Ghanim B, Thurnher D (2014) Head Neck 37:30CrossRef
14.
go back to reference Park J, Kim S, Joh J, Remick SC, Miller DM, Yan J, Kanaan Z, Chao J-H, Krem MM, Basu SK, Hagiwara S, Kenner L, Moriggl R, Bunting KD, Tse W (2016) Oncotarget 7(43960)CrossRef Park J, Kim S, Joh J, Remick SC, Miller DM, Yan J, Kanaan Z, Chao J-H, Krem MM, Basu SK, Hagiwara S, Kenner L, Moriggl R, Bunting KD, Tse W (2016) Oncotarget 7(43960)CrossRef
17.
19.
go back to reference Hu J, Li G, Liu L, Wang Y, Li X, Gong J (2017) Int J Mol Sci 18 Hu J, Li G, Liu L, Wang Y, Li X, Gong J (2017) Int J Mol Sci 18
20.
go back to reference Tiberio P, Lozneanu L, Angeloni V, Cavadini E, Pinciroli P, Callari M, Carcangiu ML, Lorusso D, Raspagliesi F, Pala V, Daidone MG, Appierto V (2017) Oncotarget 8(23246)CrossRef Tiberio P, Lozneanu L, Angeloni V, Cavadini E, Pinciroli P, Callari M, Carcangiu ML, Lorusso D, Raspagliesi F, Pala V, Daidone MG, Appierto V (2017) Oncotarget 8(23246)CrossRef
21.
Metadata
Title
AF1q Expression Associates with CD44 and STAT3 and Impairs Overall Survival in Adenoid Cystic Carcinoma of the Head and Neck
Authors
Lorenz C. Kadletz
Faris F. Brkic
Bernhard J. Jank
Sven Schneider
Julia Cede
Rudolf Seemann
Elisabeth S. Gruber
Elisabeth Gurnhofer
Gregor Heiduschka
Lukas Kenner
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00696-z

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine